Lakewood-Amedex Biotherapeutics Inc. LABT
Lakewood-Amedex Biotherapeutics Inc. (Nasdaq: LABT) is an infectious disease drug developer. Its lead program, Nu-3 (Bisphosphocin) gel, is in Phase 2 for Mildly infected diabetic foot ulcers (iDFU).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Nu-3 gel | Mildly infected diabetic foot ulcers | small molecule | Phase 2 |
| Nu-8 / Nu-10 / Nu-11 (Bisphosphocin class) | Pulmonary infections (aerosol), catheter-associated UTI | small molecule | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 infectious disease companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.